GlassScriptPhysician profile
Sushma Koneru
NPI 1457572547
$6,874.10
in general payments reported to CMS, 2019-2025
37 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.31 · 2020: $311 · 2021: $560 · 2022: $325 · 2023: $906 · 2024: $2,737 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,643.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $1,135.26 | 2023-2025 | Assure Wcd |
| Abbott Laboratories | $622.44 | 2019-2024 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $468.23 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $426.17 | 2023-2025 | Wainua, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $351.52 | 2020-2024 | Lifevest |
| Abiomed | $323.01 | 2022-2025 | Impella |
| Shockwave Medical, INC | $313.50 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cvrx, INC. | $303.68 | 2021-2025 | Barostim Neo System |
| Amgen INC. | $301.66 | 2023-2025 | Repatha |
| United Therapeutics Corporation | $283.73 | 2020-2025 | Tyvaso |
| Medtronic, INC. | $220.88 | 2023-2025 | Venaseal, Hawkone, Linq II |
| Boston Scientific Corporation | $197.55 | 2022-2025 | Watchman Access System |
| Pfizer INC. | $191.99 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $190.73 | 2024-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $175.20 | 2024-2025 | Onpattro |
Show all 35 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushma Koneru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.